Abeona Therapeutics Inc
XNAS:ABEO
| Market Cap (Intraday) | 282.04M |
| Current PE | 3.42 |
| Forward PE | 4.62 |
| 2yr Forward PE | N/A |
| 10-Day MA | $5.15 |
| 50-Day MA | $5.01 |
| 200-Day MA | $5.67 |
Abeona Therapeutics Inc Stock, XNAS:ABEO
6555 Carnegie Avenue, 4th floor, Cleveland, Ohio 44103
United States of America
Phone: +1.646.813.4701
Number of Employees: 84
Description
Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life-threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA), and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in Cleveland, OH.